glivec - Latest News on glivec | Read Breaking News on Zee News

US 'concerned' over patent norms, innovation climate in India

Last Updated: Thursday, May 02, 2013, 16:07

Raising questions over innovation climate in India, the US has said the recent decision by India's Supreme Court to prohibit patent of Novartis' cancer drug Glivec could "preclude issuance of a patent" in the country.

SC order on Novartis will impact investment in India: USIBC

Last Updated: Wednesday, April 03, 2013, 08:50

Over 40 countries including China, Russia and Taiwan have already granted a patent for Novartis' Glivec and India now stands out as unique for not granting a patent to this incremental innovation, the statement said.

'Glivec patent denial to hit investment in med advancement'

Last Updated: Monday, April 01, 2013, 23:17

Indian Supreme Court's decision Monday to deny patent to Swiss firm Novartis for its cancer drug Glivec will negatively impact the ability of companies to invest in medical and technological advancements, the US Chamber of Commerce said.

Will not invest on R&D in India, says Novartis

Last Updated: Monday, April 01, 2013, 18:19

Swiss pharma major Novartis Monday said it will not invest on research and development in India and move R&D to favourable destinations following the Supreme Court order rejecting its patent plea on cancer drug Glivec.

SC decision on Novartis to benefit poor patients: Pharma cos

Last Updated: Monday, April 01, 2013, 15:09

Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options".

Supreme Court rejects Novartis cancer drug Glivec patent plea

Last Updated: Monday, April 01, 2013, 09:27

Glivec, used in treating chronic myeloid leukemia and some other cancers, costs a patient about Rs 1.2 lakh/month, much higher than Rs 8,000 which is the price of the generic drug.

SC again asks Novartis to cut cancer drug price

Last Updated: Wednesday, September 12, 2012, 20:49

The Supreme Court Wednesday once again asked pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate.

Novartis tells SC it has right to patent its cancer drug

Last Updated: Tuesday, September 11, 2012, 20:45

The Supreme Court today asked Swiss pharma giant Novartis AG whether it should not sell its anti-cancer drug for Rs 5 each to benefit common man.